Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension (BETTER-HTN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00913094|
Recruitment Status : Unknown
Verified June 2009 by CardioDynamics.
Recruitment status was: Recruiting
First Posted : June 3, 2009
Last Update Posted : June 11, 2009
|Condition or disease|
- Patients with higher vascular resistance index and/or lower arterial compliance index will lower BP faster and to a greater degree overall when receiving vasodilating agents - such as ACEI's, ARB's, dihydropyridine CCB's, direct vasodilators, and central alpha agonists.
- Patients with an elevated cardiac index will lower BP faster and to a greater degree overall when receiving agents that reduce contractility, heart rate, or blood volume - such as beta blockers, non-dihydropyridine CCB's, and other agents that are known to reduce cardiac index.
- Patients with an elevated thoracic fluid content or lower orthostatic change in thoracic fluid content will lower BP faster and to a greater degree overall when receiving diuretics (thiazide, loop, potassium sparing), however - one of these agents will emerge as a superior alternative to reduce BP in patients with high thoracic fluid content / low orthostatic change in thoracic fluid content.
|Study Type :||Observational|
|Estimated Enrollment :||200 participants|
|Official Title:||Bioimpedance Evaluation of Therapeutic Titration in Essential, Refractory Hypertension (BETTER-HTN)|
|Study Start Date :||January 2009|
|Estimated Primary Completion Date :||January 2011|
|Estimated Study Completion Date :||June 2011|
Group will have results blinded during observational phase of study. Results will be revealed at time of testing during the validation phase of the study.
- To determine if ICG can predict therapeutic response to antihypertensive medications [ Time Frame: 2009-2010 ]
- To confirm derivation phase of ICG prediction to therapeutic response of antihypertensive medications. [ Time Frame: 2010-2011 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00913094
|United States, Michigan|
|Wayne State University||Recruiting|
|Detroit, Michigan, United States, 48201|
|Contact: Mary Maysura 313-745-2378|
|Principal Investigator: John Flack, MD|
|Principal Investigator:||John M Flack, MD||Wayne State University, and Detroit Medical Center|